It has underperformed by 56.55% the S&P500. Synovus Finance Corporation invested 0.19% in Bristol-Myers Squibb Co (NYSE:BMY). The number of shares now owned by investors are 1.67 bln. Rockefeller Financial Services Inc. now owns 25,200 shares of the biopharmaceutical company's stock worth $1,371,000 after acquiring an additional 176 shares in the last quarter. D Scott Neal accumulated 3,265 shares or 0.26% of the stock. About 12.92 million shares traded or 77.72% up from the average. First New York Securities LLC NY bought a new stake in shares of Bristol-Myers Squibb during the third quarter valued at about $108,000. It has underperformed by 39.89% the S&P500.
Jefferies downgraded Bristol-Myers Squibb Co (NYSE:BMY) on Monday, October 16 to "Hold" rating. Therefore 43% are positive. Bristol-Myers Squibb Company has $80 highest and $45 lowest target. The firm has "Sell" rating given on Sunday, July 23 by BMO Capital Markets. Finally, Citigroup Inc. boosted their price objective on shares of Bristol-Myers Squibb to $72.00 and gave the stock a "buy" rating in a report on Wednesday, October 18th. The stock of McKesson Corporation (NYSE:MCK) has "Neutral" rating given on Tuesday, June 7 by Bank of America.
Bristol-Myers Squibb Company (NYSE:BMY)'s institutional ownership stands at 70.90%. The 6 month volatility is 19.435400, and the 3 month is spotted at 19.693100. During the same period in the prior year, the company posted $0.77 EPS. After $0.75 actual EPS reported by Bristol-Myers Squibb Co for the previous quarter, Wall Street now forecasts -10.67% negative EPS growth.
Investors sentiment increased to 0.91 in Q2 2017. Its down 0.03, from 0.98 in 2017Q1. It also reduced its holding in International Business Machs (NYSE:IBM) by 4,608 shares in the quarter, leaving it with 113,695 shares, and cut its stake in Anheuser Busch Inbev Sa/Nv (NYSE:BUD). 131 funds opened positions while 449 raised stakes. Moreover, Canyon Capital Advisors Llc has 10.03% invested in the company for 19.40 million shares. D E Shaw And Co owns 3.64 million shares.
Bristol-Myers Squibb Company (BMY) have shown a high EPS growth of 4.20% in the last 5 years and has earnings rose of 184.60% yoy. Scotia Cap Incorporated holds 0.15% or 160,919 shares in its portfolio. 14,518 are owned by Reaves W H. Hl Services Limited Liability holds 0.28% or 119,362 shares.
The following firms have recently changed their position in BMY. Virtus Invest Advisers accumulated 8,113 shares. Halsey Ct stated it has 5,670 shares. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Los Angeles Capital Mngmt & Equity Research owns 1.22 million shares for 0.9% of their portfolio. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/11/14/river-mercantile-asset-management-llp-takes-869000-position-in-bristol-myers-squibb-company-bmy.html. SunTrust Banks also issued estimates for Bristol-Myers Squibb's FY2018 earnings at $3.19 EPS, FY2019 earnings at $3.64 EPS, FY2020 earnings at $4.15 EPS and FY2021 earnings at $4.40 EPS. Walleye Trading Ltd Liability Co holds 0% or 2,585 shares. Rice Hall James Assocs holds 0.01% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 4,788 shares.
Analysts await MGM Resorts International (NYSE:MGM) to report earnings on February, 15. During the same quarter a year ago, the firm posted $0.77 earnings per share. In the latest earnings report the EPS was $2.54 with 1.64B shares now outstanding. One analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company's stock. The lowest target is $32.0 while the high is $33.0. Current price places the company's stock 6.84% away from its 200-day simple moving average, -3.14%, away from the 50-day average and also -2.5% away from 20-day average. Xenon Pharmaceuticals had 14 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has "Outperform" rating by Telsey Advisory given on Tuesday, November 8. Credit Suisse maintained the shares of HIBB in report on Tuesday, July 25 with "Sell" rating. Barclays Capital maintained it with "Equal-Weight" rating and $65 target in Friday, September 9 report. The rating was maintained by Jefferies on Wednesday, October 18 with "Hold". The rating was maintained by Jefferies on Wednesday, August 23 with "Buy". The firm has "Equal-Weight" rating given on Thursday, November 9 by Morgan Stanley. More interesting news about McKesson Corporation (NYSE:MCK) were released by: Nasdaq.com and their article: "Earnings Reaction History: McKesson Corporation, 55.6% Follow-Through ..." published on October 26, 2017 as well as Twst.com's news article titled: "McKesson Corporation: Real-World Evidence from Electronic Health Record Data" with publication date: November 13, 2017. The company has a market capitalization of $92.74 billion, a price-to-earnings ratio of 27.76 and a beta of 0.94. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. It now has negative earnings.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.